Safety Profile of Psilocybin for Cocaine Use Disorder

Status Not yet recruiting

Clinical Trial Summary

The purpose of this study is to establish the safe administration of psilocybin in individuals with cocaine use disorder in terms of cardiovascular (e.g., heart rate) and subjective (e.g., mood) effects. The study's subject population consists of men and women between the ages of 21 and 55 from the Los Angeles area that meet criteria for cocaine use disorder and express an interest in ceasing cocaine use. 25 mg oral psilocybin will be administered to 10 individuals (separately) during a single laboratory visit. The laboratory visit will take place from 9 am until 3 pm within a comfortable, living room like environment. Within this study session room, participants will be accompanied by two clinicians. Participants will then consume the psilocybin capsule, and thereafter will be encouraged to lie down on a couch and introspect on the experience. At one-hour intervals following ingestion, participants will be tested briefly for changes in heart rate, blood pressure, and subjective effects. No blood draws, behavioral assessments, or neuroimaging is included in the study. Following the laboratory visit, investigators will check-in on participants remotely, after 48 hours, and 10, 50, and 90 days from the psilocybin session.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Cocaine Use Disorder

Clinical Trial Details

NCT number	NCT06102434
Study type	Interventional
Source	University of California, Los Angeles
Contact	Conor H Murray, PhD
Phone	3107943383
Email	conormurray@mednet.ucla.edu
Status	Not yet recruiting
Phase	Early Phase 1
Start date	January 2025
Completion date	December 2025

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT03538548` - Treatment Outcome in CBT for Cocaine Use	N/A
Recruiting	`NCT04994821` - tDCS to Reduce Craving in Cocaine Addiction- Phase 2 Study	Phase 2
Not yet recruiting	`NCT06050304` - CRACK-TARGET 1: ÉTUDE DESCRIPTIVE DE LA SENSIBILISATION COMPORTEMENTALE OBSERVÉE et ATTENTES
Completed	`NCT02239913` - Topiramate-Phentermine Combinations for Cocaine Dependence	Phase 1
Completed	`NCT02233647` - Phendimetrazine and Cocaine	Early Phase 1
Not yet recruiting	`NCT05974202` - rTMS and Cognitive-behavioral Therapy for Cocaine Use Disorder	Phase 2
Recruiting	`NCT04927143` - Encouraging Abstinence Behavior in a Drug Epidemic	Phase 2
Completed	`NCT03224546` - Cocaine Use Reduction and Health	N/A
Recruiting	`NCT03656653` - Imagery-based Coping for Cocaine Use Disorder	N/A
Completed	`NCT03348384` - [11C]NOP-1A and Cocaine Use Disorders	Early Phase 1
Recruiting	`NCT05019430` - Cocaine and Zolmitriptan	Early Phase 1
Recruiting	`NCT03344419` - Glutamatergic Modulation to Facilitate the Behavioral Treatment of Cocaine Use Disorders	Phase 3
Recruiting	`NCT05507814` - Temporal Window and Episodic Future Thinking in CUD	N/A
Active, not recruiting	`NCT03799341` - Neurocognitive Factors in Substance Use Treatment Response: The Ways of Rewarding Abstinence Project	N/A
Completed	`NCT02798627` - Trial Of NS2359 For The Treatment of Cocaine Dependence	Phase 2
Completed	`NCT02785406` - Role of the Orexin Receptor System in Stress, Sleep and Cocaine Use	Phase 2
Completed	`NCT02444208` - A Feasibility Trial for Inhibitory-Control Training to Reduce Cocaine Use	N/A
Recruiting	`NCT05902819` - Reconsolidation Blockade of Intrusive Trauma- and Cocaine-related Memories	N/A
Recruiting	`NCT05833529` - Innovative Cognitive and Behavioral Psychotherapy for Cocaine Use Disorder	N/A
Recruiting	`NCT05521854` - Contingency Management for Drug Use: Does Age Matter?	N/A